These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 17249259

  • 1. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A, Duggal L, Aggarwal S, Jain N.
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [Abstract] [Full Text] [Related]

  • 2. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D, Hwang W, Ng HJ, Goh YT, Tan P.
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [Abstract] [Full Text] [Related]

  • 3. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
    Payne SM, Kovacs MJ.
    Ann Pharmacother; 2004 Jul; 38(7-8):1215-8. PubMed ID: 15187212
    [Abstract] [Full Text] [Related]

  • 4. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J, Kantarjian H.
    Cancer; 2004 May 15; 100(10):2064-78. PubMed ID: 15139047
    [Abstract] [Full Text] [Related]

  • 5. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
    Salem Z, Zalloua PA, Chehal A, Bitar N, Abboud M, Kadri A, Chami B, Bazarbachi A.
    Hematol J; 2003 May 15; 4(6):410-2. PubMed ID: 14671612
    [Abstract] [Full Text] [Related]

  • 6. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP, Landry J, Roche-Lestienne C, Godon A, Schmidt-Tanguy A, Gardembas M, Le Clech C, Verret JL, Zandecki M, Blanchet O.
    Ann Biol Clin (Paris); 2005 May 15; 63(3):317-22. PubMed ID: 15951264
    [Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA.
    Curr Opin Investig Drugs; 2006 Nov 15; 7(11):980-4. PubMed ID: 17117585
    [Abstract] [Full Text] [Related]

  • 8. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
    Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G.
    Leuk Res; 2004 Jun 15; 28(6):657-60. PubMed ID: 15120945
    [Abstract] [Full Text] [Related]

  • 9. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC, Technau K, Müller AM, Lübbert M, Bruckner-Tuderman L.
    J Am Acad Dermatol; 2007 May 15; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [Abstract] [Full Text] [Related]

  • 10. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
    Schaller JL, Burkland GA.
    MedGenMed; 2001 Sep 07; 3(5):9. PubMed ID: 11698916
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
    Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H.
    Blood; 2003 Jun 15; 101(12):4714-6. PubMed ID: 12595304
    [Abstract] [Full Text] [Related]

  • 12. Hypereosinophilic syndrome: diagnosis and treatment.
    Peros-Golubicić T, Smojver-Jezek S.
    Curr Opin Pulm Med; 2007 Sep 15; 13(5):422-7. PubMed ID: 17940488
    [Abstract] [Full Text] [Related]

  • 13. The hypereosinophilic syndromes: still more heterogeneity.
    Gleich GJ, Leiferman KM.
    Curr Opin Immunol; 2005 Dec 15; 17(6):679-84. PubMed ID: 16214314
    [Abstract] [Full Text] [Related]

  • 14. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
    Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG.
    N Engl J Med; 2003 Mar 27; 348(13):1201-14. PubMed ID: 12660384
    [Abstract] [Full Text] [Related]

  • 15. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb 27; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 16. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
    Musto P, Falcone A, Sanpaolo G, Bodenizza C, Perla G, Minervini MM, Cascavilla N, Dell'Olio M, La Sala A, Mantuano S, Melillo L, Nobile M, Scalzulli PR, Bisceglia M, Carella AM.
    Leuk Lymphoma; 2004 Jun 27; 45(6):1219-22. PubMed ID: 15360005
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
    Sørensen AL, Larsen H.
    Ugeskr Laeger; 2008 Jan 21; 170(4):254. PubMed ID: 18282461
    [Abstract] [Full Text] [Related]

  • 18. Imatinib and hyperlipidemia.
    Gottardi M, Manzato E, Gherlinzoni F.
    N Engl J Med; 2005 Dec 22; 353(25):2722-3. PubMed ID: 16371644
    [No Abstract] [Full Text] [Related]

  • 19. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
    Stone RM, Gilliland DG, Klion AD.
    Semin Oncol; 2004 Apr 22; 31(2 Suppl 6):12-7. PubMed ID: 15175999
    [Abstract] [Full Text] [Related]

  • 20. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
    Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H.
    Leuk Res; 2002 Sep 22; 26(9):881-4. PubMed ID: 12127565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.